Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Kikuchi, Ken, Simone Hettmer, M. Imran Aslam, Joel E. Michalek, Wolfram Laub, Breelyn A. Wilky, David M. Loeb, Brian P. Rubin, Amy J. Wagers, and Charles Keller. 2014. “Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma.” PLoS Genetics 10 (1): e1004107. doi:10.1371/journal.pgen.1004107. http://dx.doi.org/10.1371/journal.pgen.1004107.

Published Version
doi:10.1371/journal.pgen.1004107

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879462

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma

Ken Kikuchi1, Simone Hettmer2,3, M. Imran Aslam1, Joel E. Michalek4, Wolfram Laub5, Breelyn A. Wilky6, David M. Loeb7, Brian P. Rubin8, Amy J. Wagers2, Charles Keller1*

1 Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon, United States of America, 2 The Howard Hughes Medical Institute and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States of America, and Joslin Diabetes Center, Boston, Massachusetts, United States of America, 3 Department of Pediatric Oncology, Dana Farber Cancer Institute and Division of Pediatric Hematology/Oncology, Children’s Hospital, Boston, Massachusetts, United States of America, 4 Department of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, Texas, United States of America, 5 Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, United States of America, 6 Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States of America, 7 Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States of America, 8 Departments of Anatomic Pathology and Molecular Genetics, Taussig Cancer Center and Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America

Abstract

Rhabdomyosarcoma is the most commonly occurring soft-tissue sarcoma in childhood. Most rhabdomyosarcoma falls into one of two biologically distinct subgroups represented by alveolar or embryonal histology. The alveolar subtype harbors a translocation-mediated PAX3:FOXO1A fusion gene and has an extremely poor prognosis. However, tumor cells have heterogeneous expression for the fusion gene. Using a conditional genetic mouse model as well as human tumor cell lines, we show that Pax3:Foxo1a expression is enriched in G2 and triggers a transcriptional program conducive to checkpoint adaptation under stress conditions such as irradiation in vitro and in vivo. Pax3:Foxo1a also tolerizes tumor cells to clinically-established chemotherapy agents and emerging molecularly-targeted agents. Thus, the surprisingly dynamic regulation of the Pax3:Foxo1a locus is a paradigm that has important implications for the way in which oncogenes are modeled in cancer cells.

Introduction

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. Historically, RMS has been thought to arise from muscle because of the expression of myogenic markers. Most childhood RMS falls into one of two biologically distinct subgroups: alveolar (aRMS) or embryonal (eRMS). aRMS is the more aggressive variant with a survival rate of less than 20% when metastatic due to chemotherapy and radiation resistance [1]. aRMS is characterized by a frequent t(2;13) chromosomal translocation, which results in the PAX3:FOXO1A fusion gene, or less frequently by a t(1;13) mediated PAX7:FOXO1A fusion oncogene [1]. Clinically, the aggressive behavior of aRMS has been attributed to PAX3:FOXO1A transcriptional reprogramming because fusion negative aRMS have a more favorable outcome similar to eRMS [2,3,4].

We previously developed a mouse model of aRMS employing a conditional knock-in approach that expresses Pax3:Foxo1a from the native Pax3 locus in fetal and postnatal myoblasts [5,6,7]. In this model, Pax3:Foxo1a was necessary but not sufficient for an RMS tumor initiation. Interestingly, cells expressing high levels of Pax3:Foxo1a were more prevalent in metastatic tumors [7]. The heterogeneity of Pax3:Foxo1a expression in primary and metastatic tumors, and enrichment in the latter, suggested that Pax3:Foxo1a might be selectively expressed in a subset of aRMS cells; alternatively, Pax3:Foxo1a expression might be temporally regulated. In the current study we present striking evidence that Pax3:Foxo1a is expressed in a dynamic manner and mediates a G2-specific program enabling checkpoint adaptation and refractoriness to therapy.

Results

Pax3:Foxo1a expression is dynamic in mouse aRMS cells

In our genetically-engineered conditional knock-in mouse model of aRMS, eYFP is expressed as a second cistron on the same mRNA as Pax3:Foxo1a (Figure 1A). We have observed heterogeneity of eYFP expression among tumor cells in situ (Figure 1B). To first examine Pax3:Foxo1a expression as a function of time, we flow sorted Pax3:Foxo1a+ and Pax3:Foxo1a−
Author Summary

Rare childhood cancers can be paradigms from which important new principles can be discerned. The childhood muscle cancer rhabdomyosarcoma is no exception, having been the focus of the original 1969 description by Drs. Li and Fraumeni of a syndrome now known to be commonly caused by underlying p53 tumor suppressor loss-of-function. In our studies using a conditional genetic mouse model of alveolar rhabdomyosarcoma in conjunction with human tumor cell lines, we have uncovered that the expression level of a translocation-mediated fusion gene, Pax3:Foxo1a, is dynamic and varies during the cell cycle. Our studies support that Pax3:Foxo1a facilitate the yeast-related process of checkpoint adaptation under stresses such as irradiation. The broader implication of our studies is that distal cis elements (promoter-influencing regions of DNA) may be critical to fully understanding the function of cancer-associated translocations.

Pax3:Foxo1a expression is dynamically regulated during the cell cycle

To investigate what conditions affect the dynamic alteration of Pax3:Foxo1a expression in aRMS cells, we compared eYFP fluorescence to cell cycle phase as determined by staining with the DNA dye Hoechst33342. Almost all Pax3:Foxo1a low cells existed in G2/G1 (2N) stage, while to our surprise Pax3:Foxo1a high cells were G2/M or hyperdiploid/multinuclear (≥4N) cells (Figure 1F and Figure S1D). We next performed time-lapse experiments of eYFP activity by confocal microscopy. Figure 1G shows in time-and Figure S1D). We next performed time-lapse experiments of eYFP activity by confocal microscopy. Figure 1G shows in time-
Figure 1. *eYFP activity and Pax3:Foxo1a expression is cell cycle specific.* (A) Diagrammatic representation of the conditional Pax3:Foxo1a knock-in allele by which *eYFP* is expressed as a second cistron on the same mRNA as Pax3:Foxo1a at the native Pax3 promoter. (B) Heterogeneity of *eYFP* expression in a murine aRMS tumor by immunofluorescence. (C) *eYFP* fluorescence of *eYFP* sorted cells overtime as measured by FACS. Grey:
aRMS cells lines Rh5 and Rh11 showed identical results (Figure 3). Next, we sought to understand the role of Pax3:Foxo1a in G2. For this purpose we performed genome-wide expression analysis using cells sorted at specific stages of the cell cycle (2N vs. 4N) with or without Pax3:Foxo1a siRNA knockdown (Figure 4A). Because eYFP is expressed as a second cistron in the targeted Pax3:Foxo1a-ires-eYFP allele, we anticipated that siRNA for eYFP would knock down not only eYFP but also Pax3:Foxo1a. Western blotting of Pax3:Foxo1a and native Foxo1a protein 48 hours after siRNA transfection showed that eYFP siRNA efficiently and specifically knocked down Pax3:Foxo1a protein (Figure 4B). Protein expression of the Pax3:Foxo1a transcriptional target Pdgfra was also reduced (Figure 4B).

From genome-wide expression analysis of 2N vs. 4N sorted cells with or without Pax3:Foxo1a siRNA knockdown, we found several genes implicated in the process of G2/M checkpoint adaptation to be down-regulated in G2/M (4N cells) when Pax3:Foxo1a was knocked down (Figure 4C; Table S1 shows all data analyzed by ANOVA (<0.05) using the multiple comparison correction method of Benjamini and Hochberg). Checkpoint adaptation is the process by which unicellular organisms or cancer cells progress through a delayed cell cycle checkpoint (G2 or by analogy the mitotic spindle assembly checkpoint) in lieu of programmed cell death, but before DNA damage is completely repaired [13,14,15]. Factors implicated in checkpoint adaptation are similar to those involved in checkpoint recovery (after complete repair of DNA damage), but additionally require anti-apoptotic signals [14]. Select G2/M checkpoint adaptation genes implicated in this experiment, the DNA damage sensing/checkpoint progression factors Plk1, Cdc25b, H2afx and the cell survival factor Bax3 (Sursuen), were validated for differential expression by QPCR (Figure 4D). Whether these genes are direct transcriptional targets of Pax3:Foxo1a was investigated by interrogating loci for reported nearby Pax3:Foxo1a binding sites [16]. Most potential regulatory sites were greater than 60 kb away (Table S2). While regulatory sequences can be hundreds of kb away from the target gene, it remains possible that these genes may also be regulated indirectly by other Pax3:Foxo1a target genes or miRNAs.

As a test of checkpoint adaptation and the permissiveness of aRMS cells to transit from G2 to mitosis despite single- and double-stranded DNA damage, we irradiated tumor cells with or without Pax3:Foxo1a knockdown. Radiation resulted in a higher fraction of DNA breaks amongst mitotic cells (as represented by dual pHH3 positive, H2AX positive cells) under conditions of Pax3:Foxo1a expression than its knockdown (Figure 5A and Figure S2A), suggesting that Pax3:Foxo1a does facilitate G2 to M transition, consistent with checkpoint adaptation. Moreover, we performed cell cycle and Annexin V apoptosis detection assay after treatment with 10 Gy radiation for two independent eYFP shRNA knockdown clones compared to two other independent shRNA controls (as stated early, eYFP knockdown also achieves Pax3:Foxo1a knockdown) (Figure S2). Cell cycle analysis of the shRNA clones treated with radiation revealed increasing percentage of cells in cells having ≥4N DNA content after radiation for Pax3:Foxo1a knockdown cells compared to irradiated controls (p<0.05) (Figure 5B). This result is consistent with a role of Pax3:Foxo1a in overcoming G2 arrest or M checkpoint arrest after radiation. Similarly, the Annexin V apoptosis detection assay showed a lower induction of apoptosis following radiation when Pax3:Foxo1a expression was preserved in shControl clones than shYFP cells (Figure 5C).

To test the acute role of Pax3:Foxo1a in tolerization to treatment-related DNA damage in vivo, we used eYFP siRNA to transiently knock down Pax3:Foxo1a in aRMS tumor cells treated with radiation versus non-irradiated controls that were then orthotopically injected into unirradiated host mice. Pax3:Foxo1a mediated a cell survival and tumor re-establishment advantage under the stress condition of irradiation, but not under homeostatic conditions (p = 0.02, Figure 6A and 6B).

To assess the extent to which the fusion gene mediates refractoriness to chemotherapy agents, we observed Pax3:Foxo1a to facilitate 2-4 fold refractoriness to clinical agents capable of causing double-stranded DNA breaks and mitotic arrest (vincristine, actinomycin-D, topotecan) more than agent inducing single-strand breaks (mofosfamide, the active metabolite of cyclophosphamide) (Figure S3A-E). That a similar role of Pax3:Foxo1a may apply to targeted agents was previously suggested by enriched G2 expression of Pdgfra (Figure 2F) and then demonstrated by increased sensitivity to prototypic Pdgfr inhibitor, imatinib, after Pax3:Foxo1a knockdown (Figure S3F). Similarly, Pax3:Foxo1a knockdown sensitized tumor cells to siRNA inhibition of downstream signaling mediators of acquired imatinib resistance (Figure S3G) [17]. Thus, these in vitro and in vivo results are consistent with a function of Pax3:Foxo1a in mediating checkpoint adaptation and refractoriness to the established clinical therapies of radiation and chemotherapy, or more contemporary molecularly-targeted agents.

Discussion

A key finding of this study is that Pax3:Foxo1a expression is dynamic and varies during the cell cycle. To our knowledge this is the first report of a translocation-mediated chimeric transcription factor oncogene that is expressed in a cell cycle-specific manner – much less, one that is expressed specifically during G2. The master transcription factor MYOD is expressed strongly during G1 [18] but is inactivated by phosphorylation during mitosis, which results in deportation from the nucleus [19]. MYF5 is also expressed in a cell cycle-dependent manner, but neither MYOD nor MYF5 expression is increased during G2/M as observed in our study of Pax3:Foxo1a in aRMS. Our findings reveal that Pax3 expression in wildtype C2C12 myoblasts is dynamic and increased during G2/M, but that to account for the dramatic increase in Pax3:Foxo1a expression an additional enhancer effect of Foxo1a 3’ region DNA is likely to be present. This result opens the possibility that co-factors assembled at the Pax3 promoter or fusion gene specific cis-elements might be targeted to suppress Pax3:Foxo1a expression.

Cell cycle progression after DNA damage is regulated by checkpoint controls, which prevent continued transit through the cycle until the damage has been repaired, hence protecting the integrity of the genome. Arrest in G1 permits repair prior to replication, whereas arrest in G2 allows repair prior to mitotic chromosome segregation. The p53 tumor suppressor, which is mutated in roughly half of human aRMS, has been shown to be
integral to both G1 and G2 damage checkpoint machinery, but some reports found p53 dispensable for the G2 checkpoint [13,20].

Checkpoint adaptation is defined as the ability to divide and survive following a sustained checkpoint arrest despite the presence of unrepairable DNA breaks [14]. Cells undergoing checkpoint adaptation will frequently die in subsequent cell cycles if DNA damage goes unrepaired, yet, some cells may be able to survive and proliferate in an aneuploid state [14]. Furthermore, in

---

**Figure 2. Pax3:Fxo1a activity is cell cycle dependent.** (A) mRNA expression of Pax3:Fxo1a normalized by Gapdh in U23674 mouse aRMS primary cell culture sorted by DNA content. Black lines show significant differences (p < 0.05). (B) mRNA expression of PAX3:FOXO1A normalized by GAPDH in Rh3 and Rh41 human aRMS cell lines sorted by DNA content. (C) mRNA expression of Pax3 normalized by Gapdh in C2C12 murine myoblasts sorted by DNA content. (D) Western blot analysis of Pax3 and Pax3:Fxo1a in unsorted murine U23674 aRMS cells (genotype Pax3 (Pax3:Fxo1a activated/Pax3:Fxo1a activated)), murine U57844 aRMS cells (genotype Pax3 (wt/Pax3:Fxo1a activated)), proliferative C2C12 myoblasts (pro) and differentiating C2C12 myoblasts (dif). (E) mRNA expression of Foxo1 and Pax3:Fxo1a normalized to Gapdh in C2C12 myoblasts and the U57844 mouse aRMS primary cell culture. (F) Cell cycle analysis after sorting for Pax3:Fxo1a targets Igf1r or Pdgfra in mouse aRMS tumor cells. Nearly twice as many 4N cells are Igf1r (or Pdgfra) positive versus Igf1r (or Pdgfra negative), suggesting these Pax3:Fxo1a targets may have a functional role late in the cell cycle (* P < 0.05). pos, positive. Neg, negative.

doi:10.1371/journal.pgen.1004107.g002
unicellular eukaryotes and tumor cells, DNA repair can occur at G1 [21]. Here, we reveal that the G2/M adaptation genes (H2afx, Cdc25b and Plk1) were suppressed by Pax3:Foxo1a knockdown in G2 and M cell cycle phases and that fewer cells transited from G2 to M without initiating apoptosis under conditions of Pax3:Foxo1a knockdown in the context of radiation-induced stress.

Figure 3. Pax3:Foxo1a is expressed in G2 for mouse and human aRMS. Immunocytochemistry for Pax3 (green), pH3 (red) and DAPI (blue) or Pax3 (green), pCDC2 (red) and DAPI (blue). Numbers are relative rate of Pax3:Foxo1a high or low cells/pH3 positive cells and Pax3:Foxo1a high or low cells/CDC2-Y15 high cells. Black line shows significant difference (p<0.05).
doi:10.1371/journal.pgen.1004107.g003
Figure 4. Pax3:Foxo1a induces G2/M checkpoint adaptation gene in G2/M. (A) Diagrammatic representation of Pax3:Foxo1a knockdown strategy using eYFP siRNA. (B) Knockdown of the Pax3:Foxo1a protein by siYFP. Total cell lysates were isolated 48 h after transfection. Pax3:Foxo1a was detected with an antibody targeting the C-terminus of Foxo1a. (C) Differential expression of 60 of cell cycle genes (as annotated by Gene
results suggested that not only cell cycle dependent expression but also a clinically-relevant biology underlying Pax3:Foxo1a expression at the G2-M checkpoint, a critical cell cycle checkpoint following radiation or DNA double strand break inducing-chemotherapy.

That a myogenic cancer might utilize genomic instability, aneuploidy or multicellularity as a mechanism of cell survival or tumor cell evolution/progression may not be so unexpected, in retrospect. Normal myofibers are typically multi-nuclear by definition, and genetic conditions predisposing to mitotic disjunction such as Mosaic Variegated Aneuploidy (MVA) are strongly associated with the development of RMS [22]. Both aRMS and eRMS have also been documented to be hyperdiploid, tetraploid, polyploid or to even have mixed aneuploid populations [23,24,25]. At a cellular level, the heterogeneity of cells in rhabdomyosarcoma is notable for the subpopulation of multi-nucleated rhabdomyoblasts which appears with giant nuclei or as multi-nucleated giant cells, often with cross-striations – yet highly mitotic [26]. These rhabdomyoblasts might be compared to the multicellular stemoid cells in fibrosarcoma, which have a tumor-repopulating ability [27]. Our recent study of aRMS and the PKC iota inhibitor, aurothiomalate, reveals that aRMS cells have a remarkable tolerance to polyploidy, which induces neither apoptosis or senescence [28]. This intrinsic capacity to tolerate aneuploidy as well as this report’s observed Pax3:Foxo1a-mediated increase in checkpoint adaptation gene expression may be directly relevant to clinical care, given that decreased expression of these same factors (i.e., PLK1, CCNB1, BIRC5, AURKB) have been reported to improve sensitivity to mitotic inhibitors [29]. Therefore, the interest generated from chemical screens identifying PLK1 as a potential therapeutic target in RMS [30] is likely warranted.

When considering the differences in treatment-related outcomes in RMS subtypes, the role of Pax3:Foxo1a in checkpoint adaptation may be our most important clue yet as to how to improve outcome for fusion positive patients: while aRMS are certainly sensitive to standard chemotherapy and radiation, it is the survival of resistant clones which is the cause of disease progression and relapse – which occur to a greater extent in Pax:Foxo1a positive aRMS than fusion negative aRMS or eRMS [31,32], and which we believe to be a result of Pax3:Foxo1a-mediated checkpoint adaptation. These effects on tumor cell sensitivity to radiation, chemotherapy and targeted therapeutics are likely to be cumulative and possibly critically important in defining the otherwise very narrow therapeutic window for fusion positive aRMS, for which the toxicity of chemotherapy and radiation is now dose-limiting [33].

Perhaps the most interesting aspect of this genetically-engi- neered conditional mouse model of a deadly but rare childhood cancer is that a labor-intensive knock-in approach to modeling the molecular pathophysiology of a fusion gene was beneficial. Successful transgenic tumor models have been generated by constitutive, ectopic expression of translocation-related fusion oncogenes for synovial sarcoma [34] as well as other “driver” oncogene related tumors [35]; similarly, retroviral transfection of oncogenes into hematopoietic cells has enabled this study of translocation-associated leukemia for many years [36,37]. However, are these systems driven by non-native or partial-native promoters to be the definitive preclinical platforms for interrogating molecular physiology – or are distal native cis- and trans-

---

**Materials and Methods**

**Ethics statement**

All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Oregon Health & Science University (OHSU) or the Joslin Diabetes Center (Boston, MA). Every effort was made to minimize suffering.

**Mice**

The Myf6Cre.Pax3:Foxo1a,βS3 conditional aRMS mouse model has been described previously [5,6,7], as described in caMOD Model 150064393, and is publically available through the NCI MMHCC Repository (MMHCC Strain Codes 01XBL B6; 129-Myl6-<cm2(Cre)Mrc> and 01XBM B6; 129-Pax3<cm1(Mrc>).

SHO-Pkd1Δ/ΔHβ2 mice were purchased from Charles River Laboratories (Wilmington, MA) and bred/maintained at OHSU.

**Primary tumor cell cultures and cell lines**

Mouse primary cell cultures (U23674, U42969, U57844) were established from tumor samples. Tumors were minced into small pieces and digested with collagenase (10 mg/ml) overnight at 37°C. The dissociated cells were then incubated in Dulbecco’s modified eagle’s media supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C. C2C12 mouse myoblast cells were purchased from ATCC (Manassas, VA). Human aRMS cell lines were a gift from Peter Houghton (Rh3; Nationwide Children’s Hospital, Columbus, OH) or Patrick Reynolds (Rh41; COG Cell Culture and Xenograft Repository). These cell lines were maintained in the same culture conditions as primary tumor cell cultures: DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin. All primary cell cultures experiments using cells were carried out at passage 3–7.

**Confocal imaging**

For immunofluorescence staining of frozen sections, the polyclonal antibody for green fluorescent protein (1:1000, AB16901, Chemicon) was used with DAPI counterstain.

**RNA interference studies**

siRNA transfections were carried out using Lipofectamine2000 (Invitrogen, Grand Island, NY) according to manufacturer’s recommended protocol. siRNA’s were diluted between 0.1 and 10 nM, and the final concentration of Lipofectamine2000 was 0.2%. siYFP Stealth RNAi siRNA Reporter Controls (cat. 12935-145; Invitrogen) were used as the eYFP siRNA to knockdown the Pax3:Foxo1a<eYFP bi-cistronic mRNA, whereas Stealth RNAi siRNA Negative Control Med GC #3 (cat. 12933-113; Invitrogen) was used as the siRNA control (siCont).
Dynamic Pax3:Foxo1a in Alveolar Rhabdomyosarcoma

A

count

control knockdown

pH3 H2AX foci dual positive (%)

B

difference of percentage between control and radiation cells

G2/M Super G2 G2/M Super G2 G2/M Super G2

clone A clone B clone C clone D

shControl shYFP

C

apoptosis necrosis apoptosis necrosis apoptosis necrosis

count control 10 Gy count control 10 Gy count control 10 Gy count control 10 Gy

clone A clone B clone C clone D

shControl shYFP
Generation of shRNA tumor cell culture clones

To establish shRNA knockdown clones of primary tumor cell cultures, we used MISSION pLKO.1-puro eGFP shRNA Control Transduction Particles (cat. SHC005V; Sigma Aldrich) for Pax3:Foxo1a knockdown and MISSION pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles (cat. SHC002V; Sigma Aldrich) as the control, respectively. shRNA transfections and clonal selection were carried out according to manufacturer’s recommended procedures. Mouse RMS primary cell cultures were plated at 1.8 × 10^6 cells per 150 mm dish. After 24 h, hexadimethrine bromide was added (8 μg/ml, cat. H9268; Sigma Aldrich), followed by each particle solution (MOI 0.5). After another 24 h, media were removed and fresh media were added. The following day, puromycin was added (5 μg/ml, cat. P8833; Sigma Aldrich). Puromycin-resistant clones were selected cloning rings at day 14 (shControl) and day 17 (shYFP), with continuous puromycin selection at all times.

Radiation

Cells were irradiated on a Trilogy linear accelerator (Varian, Palo Alto, CA) with a 10 × 10 cm AP field. Two centimeter of bolus material was placed on top of the 2 chamber slide or 6 cm dish and the target surface distance to the bolus was at 97 cm. Monitor units on the linear accelerator were then set to deliver 6 Gy or 10 Gy of dose to the cells.

Immunoblotting

Tumors were lysed in radioimmunoprecipitation assay (RIPA) buffer or NP40 buffer containing both protease and phosphatase inhibitor (Sigma). The lysates were homogenized and centrifuged at 8000 g for 10 minutes. The resulting supernatants were used for immunoblot analysis. Goat anti-FOXO1A antibody (cat. Sc-9808; Santa Cruz, Santa Cruz, CA), goat anti-GFP antibody (cat. 600-101-215, Rockland; Gilbertsville, PA) or rabbit anti-PDGFRα antibody (cat. #3164; Cell signaling Technology, Danvers, MA).

Figure 5. Pax3:Foxo1a facilitates G2/M checkpoint adaptation. (A) Immunocytochemistry for pHH3 (green), pH2AX (red) and DAPI (Blue) using U23674 mouse aRMS primary cell culture with or without Pax3:Foxo1a knockdown treated with 6 Gy irradiation. Black line shows significant difference (p<0.05). See Figure S2A for representative single-channel ICC images corresponding to Figure 5A. Arrowheads indicate pH3 and pH2AX double positive cells. (B) Representative cell cycle analysis for U23674 transfected by shControl (Clone A) or shYFP (Clone C) with or without 10 Gy irradiation. The graph shows the differences of percentage between control and radiated cells in shControl and shYFP clones in 3 independent experiments. Black line shows significant difference (p<0.05). (C) Annexin V apoptosis detection assay for U23674 transfected by shControl or shYFP clones with or without 10 Gy irradiation. Black line shows significant difference (p<0.05).

doi:10.1371/journal.pgen.1004107.g005

Figure 6. Treatment-related implications for dynamic oncogene expression in rhabdomyosarcoma in vivo. (A) Kaplan-Meier survival analysis for disease-free survival of mice implanted with pre-irradiated (10Gy) primary murine aRMS tumor cells treated with Pax3:Foxo1a siRNA (siY) or control siRNA (siC), n = 5 animals per cohort. The p value for the difference between siY and siC groups receiving radiation was 0.02. (B) Diagrammatic representation of results in (A).

doi:10.1371/journal.pgen.1004107.g006
1 h, and examined by confocal microscopy with a Zeiss LSM700 instrument. For immunocytochemistry experiments, at least 100 positive cells were scored per specimen.

**FACS sorting**

Cells were suspended in Hank’s balanced salt solution (HBSS) with 5% FBS and 2 mM EDTA. Antibody staining was performed for 20 minutes on ice. Prior to FACS sorting, cells were suspended in 1 μg/ml propidium iodide (PI) and 10 mM calcium blue (Invitrogen) to identify viable cells (PI -Ca²⁺). Purity checks were performed to confirm that the sorted eYFP+ and eYFP- cell subsets had a purity of >98% using a eYFP expression threshold determined by the background fluorescence of eYFP-C2x12 cells. The following antibodies were used to evaluate receptor tyrosine kinase surface expression: APC-conjugated Pdgfrα, Pax3:Foxo1a, Birc5, H2afx, and Smad4. The following primers were used to evaluate mRNA expression by RT-PCR: Pax3:Foxo1a (Mm00599915_g1), Birc5 (Mm00515990_s1), H2afx (Mm00015990_s1), Cdk2 (Mm00499136_m1), Bim3 (Mm00599-749_m1), Pik3l (Mm00440924_g1) and Gapdh (Mm99999915_g1) by Invitrogen. RT-PCR data were quantified using the standard curve method, and relative expression of Pax3:Foxo1a per sample was determined by normalization against the quantity of 18 s rRNA and Gapdh within each sample. For each sample, QPCR was performed in technical duplicates and results were averaged.

**Cell cycle analysis**

Mouse RMS primary cell cultures were trypsinized and incubated with Hoechst33342 (final concentration 15 μg/ml) and Reserpin (final concentration 5 μM). Cells were incubated in the dark for 30 min at 37°C, and analyzed and sorted by flow cytometry using an Influx FACS instrument (Becton Dickinson, Franklin Lakes, NJ). Cell cycle was determined with the FlowJo software (Tree Star, Inc., Ashland, OR).

**Annexin V apoptosis detection assay**

Mouse primary cell cultures were stained with Annexin V and Propidium iodide using Annexin-V-FLUOS Staining Kit (cat. 11 838 777 001; Roche) following the protocol provided by the manufacturer. Briefly, 48 hour after irradiation, 10⁶ mouse primary cell cultures were trypsinized, washed by PBS and resuspended in 100 μl of Annexin-V-FLUOS labeling solution, incubated 10–15 min at 15–25°C, and analyzed by FACS Calibur.

**Quantitative RT PCR (QPCR)**

U23674 cells were subfractionated by FACS sorting as described above. mRNA was isolated using RNAeasy spin columns (Qiagen, Valencia, CA) and reverse transcribed using Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). QPCR was performed using an AV7900 PCR system (Applied Biosystem) with SYBR-green PCR reagents. Pax3:Foxo1a was detected using the following primer sequences: 5’-AGA-CAGCTTTGTGCCCTCCAT-3’ and 5’-CTCTTGCCCTCCCTGGA- TT-3’. Other primers are Taqman Gene Expression assay, H2afv (Mm00015990_s1), Cdk2 (Mm00499136_m1), Bim3 (Mm00599-749_m1), Pik3l (Mm00440924_g1) and Gapdh (Mm99999915_g1) by Invitrogen. RT-PCR data were quantified using the standard curve method, and relative expression of Pax3:Foxo1a per sample was determined by normalization against the quantity of 18 s rRNA and Gapdh within each sample. For each sample, QPCR was performed in technical duplicates and results were averaged.

**In vitro growth inhibition assays**

Mouse RMS primary cell cultures were plated at 1 x 10⁵ cells of each cohort per well in a 96-well plate. After cell incubations, cytotoxic effects were assayed using CellTiter 96 AQueous One Solution Cell Proliferation Assay system (Promega, Madison, WI) and SpectraMax M5 luminometer ( Molecular Devices, Sunnyvale, CA). IC50 and C.I. were determined with CalcuSyn software (Biosoft, Cambridge, MA; in 25).

**Figure S1** This supplemental figure relates to Figure 1. eYFP activity and Pax3:Foxo1a expression is dynamic. (A) eYFP fluorescence of eYFP sorted U42369 mouse aRMS primary cell culture overtime as measured by FACS. Grey: C2x12 (negative control), blue: no sorted cells, green: eYFP activity high cells, red: eYFP activity low.
cells. (B) Mean of relative eYFP activity measured by FACS. (C) Western blot analysis using eYFP sorted cells. Plotted are relative protein levels of Pax3:Foxo1a/β-actin. Mean ± SE were obtained from three independent immunoblottings. Black line shows significant difference (p<0.05). (D) eYFP activity and cell cycle analysis using Hoechst33342 staining for mouse primary cell culture U23674. Green shows G1/G2 phase, brown shows S phase, and blue shows G2/M phase. (E–F) Proliferating mouse aRMS tumor cells were treated with 10 μg/ml CHX for the indicated incubations, and eYFP, Pax3:Foxo1a and Pdgfra protein levels were followed by western blot analysis (E). Protein expression quantified as relative flux normalized by β-actin for calculation of protein half-lives (F).

**Figure S2** This supplemental figure relates to Figure 5. Pax3:Foxo1a mediates checkpoint adaptation. (A) Individual and merged channels for immunocytochemistry of pH3 (green), pH2AX (red) and DAPI (blue) using U23674 mouse aRMS primary cell culture with or without Pax3:Foxo1a knockdown treated by 6 Gy irradiation. (B) Western blot analysis of Pax3:Foxo1a in U23674 shControl and shYFP clones.

**Figure S3** This supplemental figure relates to Figure 6. Pax3:Foxo1a modifies the aRMS therapeutic response and remains an essential target. (A–E) Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of vincristine, actinomycin-D, topotecan and eribulin by 2.9, 3.4, 4.8 and 1.8 fold, respectively, yet did not affect the IC50 of mafosfamide. (F–G) Imatinib IC50 determination using mouse aRMS tumor cells transfected with sCont or siYFP, respectively. Pax3:Foxo1a knockdown sensitized aRMS cells 5-fold to this prototypic Pdgfra inhibitor. Given the role of Pax3:Foxo1a in growth factor receptor transcription, we next explored the role of Pax3:Foxo1a in driving aberrant tyrosine kinase signaling by means of an RNAi-assisted protein target identification (RAPID) screen after first knocking down Pax3:Foxo1a in mouse aRMS tumor cells [38]. Cell viability was significantly decreased not only for targets of imatinib but also for mediators of imatinib resistance [17] in Pax3:Foxo1a knockdown cells compared with control cells (G). * p<0.01.

**Movie S1** This supplemental movie relates to Figure 1. Time lapse of eYFP expression in murine aRMS cells.

**Table S1** Genome-wide expression analysis using cell cycle specific sorted cells (2N vs 4N) with or without Pax3:Foxo1a knockdown.

**Table S2** Putative Pax3:Foxo1a binding sites of Checkpoint Adaptation related genes.

**Acknowledgments**

We are grateful to Dr. Charles R. Thomas for technical contribution to radiation studies (Department of Radiation Medicine, Oregon Health & Science University). We thank Tom Rando, Bill Forrester and Fred Barr for critical evaluation of this study during its development.

**Author Contributions**

Conceived and designed the experiments: CK KK. Performed the experiments: KK MIA SH BAW DML BPR AJW WL. Analyzed the data: CK KK JEM SH BAW DML BPR AJW. Wrote the paper: CK KK.

**References**

1. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78–85.
2. Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, et al. (2010) Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol 28: e367–388; author reply e389–390.
3. Williamson D, Musilga E, de Reyniès A, Pierron G, Thuille B, et al. (2010) Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28: 2151–2158.
4. Weiler LH, Latanyi M (2010) Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol 28: 2126–2128.
5. Keller C, Arentkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, et al. (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkh1 mice: cooperativity of Ink4a/Arf and Tgpf proIossion of function. Genes Dev 18: 2614–2626.
6. Keller C, Hansen MS, Coffin CM, Capcacci MR (2004) Pax3:Fkh1 interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma. Development 131: 3721–3734.
7. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, et al. (2009) Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 69: 2902–2911.
8. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, et al. (2008) Pax3:Fkh1 regulates gene expression in aFMS negative alveolar rhabdomyosarcoma. Oncogene 27: 6550–6560.
9. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, et al. (2010) Genome-wide identification of PACS-FKH binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 70: 6023–6027.
10. Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, et al. (2012) An adaptive Src-PDGFRa-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun 426: 363–368.
11. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78–85.
12. Berry LD, Gould KL (1996) Regulation of Cdc2 activity by phosphorylation at T14/Y15. Progress in cell cycle research 2: 99–105.
13. Syljuasen RG, Jensen S, Bartk J, Lukas J (2006) Activation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Pole-like kinase 1 kinase. Cancer Res 66: 10253–10257.
14. Syljuasen RG (2007) Checkpoint adaptation in human cells. Oncogene 26: 5853–5859.
15. Yoshi HY, Kumaagi A, Shevchenko A, Shevchenko A, Dunphy WG (2004) Adaptation of a DNA replication checkpoint response depends upon inactivation of Chaspin by the Pole-like kinase. Cell 117: 375–388.
16. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, et al. (2010) Genome-wide identification of PACS-FKH binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 70: 6023–6027.
17. Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, et al. (2012) An adaptive Src-PDGFRa-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun 426: 363–368.
18. Kitzmann M, Carnac G, Vandromme M, Primig M, Lamb NJ, et al. (1998) The fusion-negative alveolar rhabdomyosarcoma clone 2158. Cancer Res 58: 5833–5839.
19. Kowal-Vern A, Gonzalez-Crussi F, Turner J, Trujillo YP, Chou P, et al. (1990) Dynamic Pax3:Foxo1a in Alveolar Rhabdomyosarcoma. J Clin Oncol 28: e587–588; author reply e589–590.
20. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ (2001) Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20: 7453–7463.
21. Clemenson C, Marsollier-Kergoat MC (2009) DNA damage checkpoint inactivation: adaptation and recovery. DNA Repair (Amst) 8: 1101–1109.
22. Hans S, Coleman K, Reid S, Paja A, Firth H, et al. (2004) Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 36: 1159–1161.
23. Koval-Vern A, Gonzalez-Crussi F, Turner J, Trujillo YP, Chou P, et al. (1990) Flow and image cytometric DNA analysis in rhabdomyosarcoma. Cancer Res 50: 6025–6027.
24. San Miguel-Fraile P, Carrillo-Gijon R, Rodriguez-Peralto JL, Radiola IA (2004) Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in childhood rhabdomyosarcoma. Am J Clin Pathol 121: 358–365.

25. Shapiro DN, Parham DM, Douglass EC, Ashmun R, Webber BL, et al. (1991) Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J Clin Oncol 9: 159–166.

26. Li G, Kikuchi K, Radka M, Abraham J, Rubin BF, et al. (2013) IL-4 receptor blockade abrogates satellite cell–rhabdomyosarcoma fusion and prevents tumor establishment. Stem cells 31: 2304–12.

27. Weihs Z, Lin Q, Ranoth A, Fan D, Fidler IJ (2011) Formation of solid tumors by a single multinucleated cancer cell. Cancer 117: 4092–4099.

28. Kikuchi K, Soundararajan A, Zarrabal LA, Wehrn CR, Nelson LD, et al. (2012) Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 32: 286–95.

29. Yamada HY, Rao CV (2010) Genes that modulate the sensitivity for antimitotubule drug-mediated chemotherapy. Curr Cancer Drug Targets 10: 623–633.

30. Hu K, Lee C, Qiu D, Fotovati A, Davies A, et al. (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8: 3024–3035.

31. Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, et al. (2013) PAX-FOXO1 Fusion Status Drives Unfavorable Outcome for Children With Rhabdomyosarcoma: A Children’s Oncology Group Report. Pediatr Blood Cancer 60: 1411–7.

32. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, et al. (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30: 1670–1677.

33. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, et al. (2012) Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer 118: 1130–1137.

34. Haldar M, Hancock JD, Coffin CM, Lesnick SL, Capezzi MR (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11: 375–388.

35. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woodfenden S, et al. (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 106: 2712–2716.

36. Berri RM, Zhu N, Sinha AU, Vempati S, Faber J, et al. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66–78.

37. DeMartino JF, Miller T, Ayton PM, Landeau T, Hess JL, et al. (2000) A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96: 3897–3893.

38. Tyner JW, Walters DK, Willis SG, Luttrell M, Oost J, et al. (2008) RNAi screening of the tyrosine kinase identifies therapeutic targets in acute myeloid leukemia. Blood 111: 2230–2245.